Literature DB >> 23836591

Validation of an algorithm to identify antiretroviral-naïve status at time of entry into a large, observational cohort of HIV-infected patients.

Neel R Gandhi1, Janet P Tate, Maria C Rodriguez-Barradas, David Rimland, Matthew Bidwell Goetz, Cynthia Gibert, Sheldon T Brown, Kristin Mattocks, Amy C Justice.   

Abstract

PURPOSE: Large, observational HIV cohorts play an important role in answering questions which are difficult to study in randomized trials; however, they often lack detailed information regarding previous antiretroviral treatment (ART). Knowledge of ART treatment history is important when ascertaining the long-term impact of medications, co-morbidities, or adverse reactions on HIV outcomes.
METHODS: We performed a retrospective study to validate a prediction algorithm for identifying ART-naïve patients using the Veterans Aging Cohort Study's Virtual Cohort-an observational cohort of 40 594 HIV-infected veterans nationwide. Medical records for 3070 HIV-infected patients were reviewed to determine history of combination ART treatment. An algorithm using Virtual Cohort laboratory data was used to predict ART treatment status and compared to medical record review.
RESULTS: Among 3070 patients' medical records reviewed, 1223 were eligible for analysis. Of these, 990 (81%) were ART naïve at cohort entry based on medical record review. The prediction algorithm's sensitivity was 86%, specificity 47%, positive predictive value (PPV) 87%, and negative predictive value 45%, using a viral load threshold of <400 copies/ml. Sensitivity analysis revealed that PPV would be maximized by increasing the viral load threshold, whereas sensitivity would be maximized by lowering the viral load threshold.
CONCLUSIONS: A prediction algorithm using available laboratory data can be used to accurately identify ART-naïve patients in large, observational HIV cohorts. Use of this algorithm will allow investigators to accurately limit analyses to ART-naïve patients when studying the contribution of ART to outcomes and adverse events.
Copyright © 2013 John Wiley & Sons, Ltd.

Entities:  

Keywords:  HIV infections/drug therapy; HIV infections/epidemiology; HIV-1; antiretroviral therapy; cohort studies; pharmacoepidemiology

Mesh:

Substances:

Year:  2013        PMID: 23836591      PMCID: PMC3831617          DOI: 10.1002/pds.3476

Source DB:  PubMed          Journal:  Pharmacoepidemiol Drug Saf        ISSN: 1053-8569            Impact factor:   2.890


  24 in total

1.  Cohort profile: the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD).

Authors:  Stephen J Gange; Mari M Kitahata; Michael S Saag; David R Bangsberg; Ronald J Bosch; John T Brooks; Liviana Calzavara; Steven G Deeks; Joseph J Eron; Kelly A Gebo; M John Gill; David W Haas; Robert S Hogg; Michael A Horberg; Lisa P Jacobson; Amy C Justice; Gregory D Kirk; Marina B Klein; Jeffrey N Martin; Rosemary G McKaig; Benigno Rodriguez; Sean B Rourke; Timothy R Sterling; Aimee M Freeman; Richard D Moore
Journal:  Int J Epidemiol       Date:  2007-01-08       Impact factor: 7.196

Review 2.  Cohort Profile: Caribbean, Central and South America Network for HIV research (CCASAnet) collaboration within the International Epidemiologic Databases to Evaluate AIDS (IeDEA) programme.

Authors:  Catherine C McGowan; Pedro Cahn; Eduardo Gotuzzo; Denis Padgett; Jean W Pape; Marcelo Wolff; Mauro Schechter; Daniel R Masys
Journal:  Int J Epidemiol       Date:  2007-09-10       Impact factor: 7.196

3.  Hyperlactatemia and antiretroviral therapy: the Swiss HIV Cohort Study.

Authors:  K Boubaker; M Flepp; P Sudre; H Furrer; A Haensel; B Hirschel; K Boggian; J P Chave; E Bernasconi; M Egger; M Opravil; M Rickenbach; P Francioli; A Telenti
Journal:  Clin Infect Dis       Date:  2001-10-23       Impact factor: 9.079

4.  Impact of individual antiretroviral drugs on the risk of myocardial infarction in human immunodeficiency virus-infected patients: a case-control study nested within the French Hospital Database on HIV ANRS cohort CO4.

Authors:  Sylvie Lang; Murielle Mary-Krause; Laurent Cotte; Jacques Gilquin; Marialuisa Partisani; Anne Simon; Franck Boccara; Dominique Costagliola
Journal:  Arch Intern Med       Date:  2010-07-26

5.  Effect of age and HAART regimen on clinical response in an urban cohort of HIV-infected individuals.

Authors:  Adena H Greenbaum; Lucy E Wilson; Jeanne C Keruly; Richard D Moore; Kelly A Gebo
Journal:  AIDS       Date:  2008-11-12       Impact factor: 4.177

6.  Class of antiretroviral drugs and the risk of myocardial infarction.

Authors:  Nina Friis-Møller; Peter Reiss; Caroline A Sabin; Rainer Weber; Antonella d'Arminio Monforte; Wafaa El-Sadr; Rodolphe Thiébaut; Stephane De Wit; Ole Kirk; Eric Fontas; Matthew G Law; Andrew Phillips; Jens D Lundgren
Journal:  N Engl J Med       Date:  2007-04-26       Impact factor: 91.245

7.  Racial differences in end-stage renal disease rates in HIV infection versus diabetes.

Authors:  Andy I Choi; Rudolph A Rodriguez; Peter Bacchetti; Daniel Bertenthal; Paul A Volberding; Ann M O'Hare
Journal:  J Am Soc Nephrol       Date:  2007-10-17       Impact factor: 10.121

8.  Risk factors for treatment-limiting toxicities in patients starting nevirapine-containing antiretroviral therapy.

Authors:  Anouk M Kesselring; Ferdinand W Wit; Caroline A Sabin; Jens D Lundgren; M John Gill; Jose M Gatell; Andri Rauch; Julio S Montaner; Frank de Wolf; Peter Reiss; Amanda Mocroft
Journal:  AIDS       Date:  2009-08-24       Impact factor: 4.177

9.  Delayed presentation for human immunodeficiency virus (HIV) care among veterans: a problem of access or screening?

Authors:  Neel R Gandhi; Melissa Skanderson; Kirsha S Gordon; John Concato; Amy C Justice
Journal:  Med Care       Date:  2007-11       Impact factor: 2.983

10.  Hepatitis C and the risk of kidney disease and mortality in veterans with HIV.

Authors:  Michael J Fischer; Christina M Wyatt; Kirsha Gordon; Cynthia L Gibert; Sheldon T Brown; David Rimland; Maria C Rodriguez-Barradas; Amy C Justice; Chirag R Parikh
Journal:  J Acquir Immune Defic Syndr       Date:  2010-02       Impact factor: 3.731

View more
  9 in total

1.  Evaluating the incident user design in the HIV population: incident use versus naive?

Authors:  Emily S Brouwer; Daniela C Moga; Joseph J Eron; Sonia Napravnik
Journal:  Pharmacoepidemiol Drug Saf       Date:  2014-09-25       Impact factor: 2.890

2.  Risk of liver decompensation with cumulative use of mitochondrial toxic nucleoside analogues in HIV/hepatitis C virus coinfection.

Authors:  Vincent Lo Re; Bret Zeldow; Michael J Kallan; Janet P Tate; Dena M Carbonari; Sean Hennessy; Jay R Kostman; Joseph K Lim; Matthew Bidwell Goetz; Robert Gross; Amy C Justice; Jason A Roy
Journal:  Pharmacoepidemiol Drug Saf       Date:  2017-07-19       Impact factor: 2.890

3.  Antiretroviral therapy reduces the rate of hepatic decompensation among HIV- and hepatitis C virus-coinfected veterans.

Authors:  Jeffrey P Anderson; Eric J Tchetgen Tchetgen; Vincent Lo Re; Janet P Tate; Paige L Williams; George R Seage; C Robert Horsburgh; Joseph K Lim; Matthew Bidwell Goetz; David Rimland; Maria C Rodriguez-Barradas; Adeel A Butt; Marina B Klein; Amy C Justice
Journal:  Clin Infect Dis       Date:  2013-11-27       Impact factor: 9.079

4.  Weight change after antiretroviral therapy and mortality.

Authors:  Bianca Yuh; Janet Tate; Adeel A Butt; Kristina Crothers; Matthew Freiberg; David Leaf; Mary Logeais; David Rimland; Maria C Rodriguez-Barradas; Christopher Ruser; Amy C Justice
Journal:  Clin Infect Dis       Date:  2015-03-11       Impact factor: 9.079

5.  The impact of prescribed opioids on CD4 cell count recovery among HIV-infected patients newly initiating antiretroviral therapy.

Authors:  E J Edelman; K S Gordon; J P Tate; W C Becker; K Bryant; K Crothers; J R Gaither; C L Gibert; A J Gordon; Bdl Marshall; M C Rodriguez-Barradas; J H Samet; M Skanderson; A C Justice; D A Fiellin
Journal:  HIV Med       Date:  2016-11       Impact factor: 3.180

6.  Hepatic decompensation in antiretroviral-treated patients co-infected with HIV and hepatitis C virus compared with hepatitis C virus-monoinfected patients: a cohort study.

Authors:  Vincent Lo Re; Michael J Kallan; Janet P Tate; A Russell Localio; Joseph K Lim; Matthew Bidwell Goetz; Marina B Klein; David Rimland; Maria C Rodriguez-Barradas; Adeel A Butt; Cynthia L Gibert; Sheldon T Brown; Lesley Park; Robert Dubrow; K Rajender Reddy; Jay R Kostman; Brian L Strom; Amy C Justice
Journal:  Ann Intern Med       Date:  2014-03-18       Impact factor: 25.391

7.  Tenofovir-Associated Bone Adverse Outcomes among a US National Historical Cohort of HIV-Infected Veterans: Risk Modification by Concomitant Antiretrovirals.

Authors:  Joanne LaFleur; Adam P Bress; Joel Myers; Lisa Rosenblatt; Jacob Crook; Kristin Knippenberg; Roger Bedimo; Pablo Tebas; Heather Nyman; Stephen Esker
Journal:  Infect Dis Ther       Date:  2018-02-28

8.  Cardiovascular outcomes among HIV-infected veterans receiving atazanavir.

Authors:  Joanne LaFleur; Adam P Bress; Lisa Rosenblatt; Jacob Crook; Paul E Sax; Joel Myers; Corey Ritchings
Journal:  AIDS       Date:  2017-09-24       Impact factor: 4.177

9.  Trends in Comorbid Conditions Among Medicaid Enrollees With HIV.

Authors:  Megan B Cole; Omar Galárraga; Momotazur Rahman; Ira B Wilson
Journal:  Open Forum Infect Dis       Date:  2019-03-10       Impact factor: 3.835

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.